IDT Australia Ltd.   Report issue

For profit Phase 1
Founded: Boronia Australia (1986)

Organization Overview

First Clinical Trial
2012
NCT01787747
First Marketed Drug
1986
procainamide (pronestyl)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

CMAX | CMAX - A division of IDT Australia, Limited | CMAX, A Division of IDT Australia, Limited | CMAX (A division of IDT Australia Ltd) | CMAX - Clinical Research Pty Ltd, Level 5, 18a North Terrace, Adelaide, South Australia, 5000, Australia | CMAX Ltd | c/o CMAX - a division of IDT Australia Ltd. | IDT AUSTRALIA LTD | IDT CMAX | IDT CMAX Clinical Trials

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 1)

Hepatitis B (Phase 1)

Hepatitis B, Chronic (Phase 1)

Lupus Erythematosus, Systemic (Phase 1)

Multiple Sclerosis (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 14
  • # of Trial APIs: 16